LMX1A
Basic information
Region (hg38): 1:165201867-165356715
Previous symbols: [ "LMX1" ]
Links
Phenotypes
GenCC
Source:
- autosomal dominant nonsyndromic hearing loss 7 (Strong), mode of inheritance: AD
- autosomal dominant nonsyndromic hearing loss 7 (Limited), mode of inheritance: AD
- autosomal dominant nonsyndromic hearing loss 7 (Strong), mode of inheritance: AD
- autosomal dominant nonsyndromic hearing loss 7 (Limited), mode of inheritance: AD
- hearing loss, autosomal recessive (Limited), mode of inheritance: AR
- Mobius syndrome (Limited), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Deafness, autosomal dominant 7 | AD | Audiologic/Otolaryngologic | Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development | Audiologic/Otolaryngologic | 29754270 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (38 variants)
- not_provided (15 variants)
- LMX1A-related_disorder (15 variants)
- Autosomal_dominant_nonsyndromic_hearing_loss_7 (14 variants)
- Schizophrenia (1 variants)
- Autosomal-Recessive_Hereditary_Hearing_Impairment (1 variants)
- Sensorineural_hearing_loss_disorder (1 variants)
- Monogenic_hearing_loss (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the LMX1A gene is commonly pathogenic or not. These statistics are base on transcript: NM_000177398.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 7 | |||||
| missense | 48 | 56 | ||||
| nonsense | 4 | |||||
| start loss | 0 | |||||
| frameshift | 2 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 4 | 5 | 51 | 6 | 3 |
Highest pathogenic variant AF is 0.00001177166
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| LMX1A | protein_coding | protein_coding | ENST00000342310 | 8 | 154849 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.991 | 0.00886 | 125725 | 0 | 6 | 125731 | 0.0000239 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 1.00 | 175 | 216 | 0.808 | 0.0000114 | 2500 |
| Missense in Polyphen | 56 | 91.757 | 0.61031 | 1036 | ||
| Synonymous | 0.565 | 82 | 88.8 | 0.924 | 0.00000482 | 725 |
| Loss of Function | 4.06 | 2 | 23.0 | 0.0870 | 0.00000132 | 232 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0000615 | 0.0000615 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.000139 | 0.000139 |
| European (Non-Finnish) | 0.0000176 | 0.0000176 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.00 | 0.00 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Acts as a transcriptional activator by binding to an A/T-rich sequence, the FLAT element, in the insulin gene promoter. Required for development of the roof plate and, in turn, for specification of dorsal cell fates in the CNS and developing vertebrae (By similarity). {ECO:0000250}.;
- Pathway
- Dopaminergic Neurogenesis
(Consensus)
Recessive Scores
- pRec
- 0.230
Intolerance Scores
- loftool
- 0.0623
- rvis_EVS
- -0.74
- rvis_percentile_EVS
- 13.94
Haploinsufficiency Scores
- pHI
- 0.370
- hipred
- Y
- hipred_score
- 0.699
- ghis
- 0.510
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.986
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Lmx1a
- Phenotype
- integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; taste/olfaction phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; pigmentation phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype;
Gene ontology
- Biological process
- regulation of cell growth;axon guidance;memory;locomotory behavior;dentate gyrus development;cerebellum development;olfactory behavior;negative regulation of neuron differentiation;positive regulation of transcription by RNA polymerase II;synapse organization;dopaminergic neuron differentiation;midbrain dopaminergic neuron differentiation
- Cellular component
- nucleus
- Molecular function
- RNA polymerase II regulatory region sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;protein binding;metal ion binding